Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12128MR)

This product GTTS-WQ12128MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12128MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3099MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ2025MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ7060MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ13698MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ11080MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ13171MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ7524MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ9022MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW